Induced Pluripotent Stem Cells Reduce Progression of Experimental Chronic Kidney Disease but Develop Wilms' Tumors

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2017 Aug 29

PMID 28845162

Citations 19

Authors

Heloisa Cristina Caldas

Fernando Henrique Lojudice

Cinthia Dias

Ida Maria Maximina Fernandes-Charpiot

Maria Alice Sperto Ferreira Baptista

Rosa Sayoko Kawasaki-Oyama

Mari Cleide Sogayar

Christina Maeda Takiya

Mario Abbud-Filho

Affiliations

Soon will be listed here.

Abstract

The therapeutic effect of induced pluripotent stem cells (iPSs) on the progression of chronic kidney disease (CKD) has not yet been demonstrated. In this study, we sought to assess whether treatment with iPSs retards progression of CKD when compared with bone marrow mesenchymal stem cells (BMSCs). Untreated 5/6 nephrectomized rats were compared with CKD animals receiving BMSCs or iPSs. Renal function, histology, immunohistochemistry, and gene expression were studied. Implanted iPSs were tracked by the SRY gene expression analysis. Both treatments minimized elevation in serum creatinine, significantly improved clearance, and slowed down progression of disease. The proteinuria was reduced only in the iPS group. Both treatments reduced glomerulosclerosis, iPSs decreased macrophage infiltration, and TGF- was reduced in kidneys from the BMSC group. Both types of treatments increased VEGF gene expression, TGF- was upregulated only in the iPS group, and IL-10 had low expression in both groups. The SRY gene was found in 5/8 rats treated with iPSs. These 5 animals presented tumors with histology and cells highly staining positive for PCNA and Wilms' tumor protein antibody characteristics of Wilms' tumor. These results suggest that iPSs may be efficient to retard progression of CKD but carry the risk of Wilms' tumor development.

Citing Articles

Modeling high-risk Wilms tumors enables the discovery of therapeutic vulnerability.

Ma G, Gao A, Chen J, Liu P, Sarda R, Gulliver J Cell Rep Med. 2024; 5(10):101770.

PMID: 39368485 PMC: 11513831. DOI: 10.1016/j.xcrm.2024.101770.

Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.

Taherian M, Bayati P, Mojtabavi N Stem Cell Res Ther. 2024; 15(1):170.

PMID: 38886859 PMC: 11184790. DOI: 10.1186/s13287-024-03782-5.

Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives.

Wang Y, Jin M, Cheng C, Li Q Front Endocrinol (Lausanne). 2023; 14:1238927.

PMID: 37600689 PMC: 10433744. DOI: 10.3389/fendo.2023.1238927.

Review on kidney diseases: types, treatment and potential of stem cell therapy.

Singh J, Singh S Ren Replace Ther. 2023; 9(1):21.

PMID: 37131920 PMC: 10134709. DOI: 10.1186/s41100-023-00475-2.

Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome.

Liu C, Xiao K, Xie L Front Cell Dev Biol. 2022; 10:951764.

PMID: 36036014 PMC: 9399751. DOI: 10.3389/fcell.2022.951764.

References

Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K . In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007; 448(7151):318-24. DOI: 10.1038/nature05944. View

Dekel B, Metsuyanim S, Schmidt-Ott K, Fridman E, Jacob-Hirsch J, Simon A . Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. Cancer Res. 2006; 66(12):6040-9. DOI: 10.1158/0008-5472.CAN-05-4528. View

Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T . Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2007; 26(1):101-6. DOI: 10.1038/nbt1374. View

Andrews P, Matin M, Bahrami A, Damjanov I, Gokhale P, Draper J . Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin. Biochem Soc Trans. 2005; 33(Pt 6):1526-30. DOI: 10.1042/BST0331526. View

Chung Y, Ma M, Huang B, Chiang H, Chou S . Protection of bone marrow-derived CD45+/CD34-/lin- stromal cells with immunosuppressant activity against ischemia/reperfusion injury in rats. Chin J Physiol. 2011; 54(3):169-82. DOI: 10.4077/cjp.2011.amm019. View

Morita M, Mii A, Shimizu A, Yasuda F, Shoji J, Masuda Y . Glomerular endothelial cell injury and focal segmental glomerulosclerosis lesion in idiopathic membranous nephropathy. PLoS One. 2015; 10(4):e0116700. PMC: 4398543. DOI: 10.1371/journal.pone.0116700. View

Damjanov I, Andrews P . The terminology of teratocarcinomas and teratomas. Nat Biotechnol. 2007; 25(11):1212. DOI: 10.1038/nbt1107-1212a. View

Toyohara T, Mae S, Sueta S, Inoue T, Yamagishi Y, Kawamoto T . Cell Therapy Using Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute Kidney Injury in Mice. Stem Cells Transl Med. 2015; 4(9):980-92. PMC: 4542865. DOI: 10.5966/sctm.2014-0219. View

Ellison D, Silverman J, Strausbauch P, Wakely P, Holbrook C, JOSHI V . Role of immunocytochemistry, electron microscopy, and DNA analysis in fine-needle aspiration biopsy diagnosis of Wilms' tumor. Diagn Cytopathol. 1996; 14(2):101-7. DOI: 10.1002/(SICI)1097-0339(199603)14:2<101::AID-DC1>3.0.CO;2-M. View

10.

Rivera M, Haber D . Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer. 2005; 5(9):699-712. DOI: 10.1038/nrc1696. View

11.

Crary G, Swan S, ODonnell M, Kasiske B, Katz S, Keane W . The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats. J Am Soc Nephrol. 1995; 6(4):1295-9. DOI: 10.1681/ASN.V641295. View

12.

Presser Aiden A, Rivera M, Rheinbay E, Ku M, Coffman E, Truong T . Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell. 2010; 6(6):591-602. PMC: 2897075. DOI: 10.1016/j.stem.2010.03.016. View

13.

Caldas H, de Paula Couto T, Fernandes I, Baptista M, Kawasaki-Oyama R, Goloni-Bertollo E . Comparative effects of mesenchymal stem cell therapy in distinct stages of chronic renal failure. Clin Exp Nephrol. 2015; 19(5):783-9. DOI: 10.1007/s10157-015-1079-1. View

14.

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

15.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

16.

Alexandre C, Volpini R, Shimizu M, Sanches T, Semedo P, di Jura V . Lineage-negative bone marrow cells protect against chronic renal failure. Stem Cells. 2008; 27(3):682-92. DOI: 10.1634/stemcells.2008-0496. View

17.

Guha P, Morgan J, Mostoslavsky G, Rodrigues N, Boyd A . Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell. 2013; 12(4):407-12. DOI: 10.1016/j.stem.2013.01.006. View

18.

Shukrun R, Pode Shakked N, Dekel B . Targeted therapy aimed at cancer stem cells: Wilms' tumor as an example. Pediatr Nephrol. 2013; 29(5):815-23. DOI: 10.1007/s00467-013-2501-0. View

19.

Ben-Porath I, Thomson M, Carey V, Ge R, Bell G, Regev A . An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008; 40(5):499-507. PMC: 2912221. DOI: 10.1038/ng.127. View

20.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View